上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Nilotinib (Synonyms: 尼洛替尼; AMN107) 纯度: 99.82%
Nilotinib是一种口服可用的具有抗肿瘤活性的 Bcr-Abl 酪氨酸激酶抑制剂。
Nilotinib Chemical Structure
CAS No. : 641571-10-0
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
25 mg | ¥350 | In-stock | |
50 mg | ¥550 | In-stock | |
100 mg | ¥850 | In-stock | |
200 mg | ¥1250 | In-stock | |
500 mg | ¥2500 | In-stock | |
1 g | 询价 | ||
5 g | 询价 |
* Please select Quantity before adding items.
Nilotinib 相关产品
•相关化合物库:
- Drug Repurposing Compound Library Plus
- FDA-Approved Drug Library Plus
- FDA-Approved Drug Library Mini
- Bioactive Compound Library Plus
生物活性 |
Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. |
IC50 & Target |
Bcr-Abl[1] |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
The novel, selective Abl inhibitor, Nilotinib (AMN107), is designed to interact with the ATP-binding site of BCR-ABL with a higher affinity than Imatinib. In addition to being significantly more potent compared with Imatinib (IC50<30 nm), nilotinib also maintains activity against most of the bcr-abl point mutants that confer imatinib resistance[1]. Nilotinib demonstrates significant antitumor efficacy against GIST xenograft lines and Imatinib-resistant GIST cell lines. The parent cell lines GK1C and GK3C show Imatinib sensitivity with IC50 of 4.59±0.97 µM and 11.15±1.48 µM, respectively. The Imatinib-resistant cell lines GK1C-IR and GK3C-IR show Imatinib resistance with IC50 values of 11.74±0.17 µM (P<0.001) and 41.37±1.07 µM (P<0.001), respectively[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
体内研究 (In Vivo) |
The percentage of tumor growth inhibition (TGI) is 83.8% for Imatinib and 69.6% for Nilotinib in the GK1X xenograft line (n.s.). In the GK2X xenograft line, TGI is 83.0% for Imatinib and 85.3% for Nilotinib (n.s.). Additionally, the GK3X xenograft line TGI is 31.1% for Imatinib and 47.5% for Nilotinib (n.s.). These results suggest that, except for the GK1X xenograft line, Nilotinib shows equivalent or higher antitumor effects than Imatinib[2]. Nilotinib has a significant healing effect on the macroscopic and microscopic pathologic scores and ensures considerable mucosal healing in the indomethacin-induced enterocolitis rat model. While Nilotinib decreased the PDGFR α and β levels and apoptotic scores in the colon, it did not have a significant effect on the weight and TNF-α levels. Further experimental investigations could provide more definitive evidence for humans[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
Clinical Trial |
|
||||||||||||
分子量 |
529.52 |
||||||||||||
Formula |
C28H22F3N7O |
||||||||||||
CAS 号 |
641571-10-0 |
||||||||||||
中文名称 |
尼洛替尼;尼罗替尼 |
||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||
储存方式 |
|
||||||||||||
溶解性数据 |
In Vitro:
DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble or slightly soluble) In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||
参考文献 |
|
Cell Assay [2] |
The human GIST cell lines GK1C and GK3C, and the Imatinib-resistant cell lines GK1C-IR and GK3C-IR are plated in 96-well microplates and cultured for 12 h before exposure to Imatinib (1-100 µM) or Nilotinib (1-100 µM) for 72 h. The cells are quantified by the WST-8 assay. The optical density (OD) is determined with Sunrise rainbow. The rate of inhibition is calculated as follows: % of inhibition=(OD of treated group-blank)/(OD of control group-blank)×100%. The concentration of tested drugs resulting in 50% growth inhibition (IC50) is calculated[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
Animal Administration [2][3] |
Mice[2] 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务